Discussing the potential of PARP-inhibitor, Lynparza (olaparib), in combination with abiraterone for patients with mCRPC

Executed on:Nov 1, 2022 11:00 AM EDT

Call Duration:30 minutes

Expert Profile

ExpertBlinded Expert

Institution: Providence Saint Joseph HealthBoard certified Medical Oncologist at Providence Saint Joseph Health & member of the Cancer Commitee at Henry Mayo Hospital.
Manages 36 patients with metastatic castration-resistant prostate cancer.
Over 20 years of experience and serves as a member of hospital's P&T committee,

Interview Goal

This conversation will focus on the potential  Lynparza in patients with metastatic castration-resistant prostate cancer and looking at the results from the Phase 3 PROpel study of olaparib in combination with abiraterone for patients with mCRPC.

Slingshot Insights Explained

Expert research benefits investors by giving them timely access to unbiased real world perspectives on highly specialized topics. Slingshot Insights' crowdfunded model makes this access available at a fraction of the cost of other expert networks.